Middle East & Africa Radioactive Tracer Market Forecast to 2030 - Regional Analysis - by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium

Middle East & Africa Radioactive Tracer Market Forecast to 2030 - Regional Analysis - by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others), and End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, and Others)

The Middle East & Africa radioactive tracer market was valued at US$ 268.57 million in 2022 and is expected to reach US$ 602.69 million by 2030; it is estimated to grow at a CAGR of 10.6% from 2022 to 2030.

Increasing Use of Nuclear Imaging Techniques fuel the Middle East & Africa Radioactive Tracer Market

PET and SPECT are among the nuclear medicine radiology modalities employed in clinical settings. Their use is increasing as they offer accurate detection, localization, and characterization of diseases. Ionizing radiation for diagnosis and treatment benefits millions of patients globally. Radiation in medicine helps earlier diagnosis and often offers less invasive treatments for human diseases. Advanced radiation technology has opened new horizons in diagnostic and nuclear medicine, radiotherapy, and interventional radiology. According to World Health Organization, over 3,600 million diagnostic radiology examinations are performed, 37 million nuclear medicine procedures are carried out, and 7.5 million radiotherapy treatments are given annually. The development and introduction of new radiopharmaceuticals for PET/CT and SPECT/CT procedures, which are used in novel clinical applications such as neurology and orthopedics, and the growing accuracy of different tumor staging methods contribute to the growth of the radioactive tracer market. For instance, newly introduced cardiac radiopharmaceuticals such as flurpiridaz F-18 and ammonia N-13 help in more precise imaging of cardiovascular conditions. Thus, constant technological advancements for improving the quality and efficacy of nuclear imaging techniques favor the growth of the radioactive tracer market.

Middle East & Africa Radioactive Tracer Market Overview

The Middle East & Africa radioactive tracer market is segmented into UAE, South Africa, Saudi Arabia and the Rest of Middle East & Africa. The regional growth is attributed to technological advancements and developments by market players offering radioactive tracer. Factors such as the rising healthcare infrastructure and the increasing number of chronic diseases, advancements in medical imaging and rising healthcare infrastructure are likely to further propel the market growth during the forecast period.

Middle East & Africa Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Radioactive Tracer Market Segmentation

The Middle East & Africa radioactive tracer market is segmented based on tracer type, test type, end user, application, and country. Based on tracer type, the Middle East & Africa radioactive tracer market is segmented into technetium-99m & Tc-97m, iodine-131, iron-59, lutetium-171, rubidium (Rb-82) chloride & ammonia (N-13), scandium-46, seaborgium-269, hassium-269, Gallium citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), phosphorus-32 & chromium-51, thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and others. The others segment held the largest market share in 2022.

Based on test type, the Middle East & Africa radioactive tracer market is segmented into PET, SPECT, and others. The SPECT segment held the largest market share in 2022.

Based on end user, the Middle East & Africa radioactive tracer market is segmented into hospitals & clinics, diagnostic centers, academic & research institutes, and others. The hospitals & clinics segment held the largest market share in 2022.

Based on application, the Middle East & Africa radioactive tracer market is segmented into oncology, pulmonary, neurology, cardiology, and others. The oncology segment held the largest market share in 2022.

Based on country, the Middle East & Africa radioactive tracer market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa radioactive tracer market share in 2022.

Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, and IBA Radiopharma Solutions are some of the leading players operating in the Middle East & Africa radioactive tracer market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa radioactive tracer market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa radioactive tracer market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa radioactive tracer market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution